# US 2022/0017909 A1 · Methods and compositions for treating hyperoxaluria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017909 A1
- Document ID: US20220017909A1
- Status: Published application
- Kind: A1
- Application number: 17/312,166
- Filed: 2019-12-10
- Published: 2022-01-20
- Earliest claimed: 2018-12-10
- Assignees: Novome Biotechnologies, Inc.
- Applicants: Novome Biotechnologies, Inc.
- Inventors: Zachary Nicholas Russ IV; Weston Robert Whitaker; William Cain DeLoache; Elizabeth Joy Stanley Shepherd
- Web page: https://patentgrep.com/patent/US20220017909A1

## CPC

- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- C12N 1/205: Bacterial isolates
- C12N 9/0008: {acting on the aldehyde or oxo group of donors (1.2)}
- C12N 9/13: {transferring sulfur containing groups (2.8)}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12Y 102/03004: Oxalate oxidase (1.2.3.4)
- C12N 9/88: Lyases (4.)
- C12N 9/93: {Ligases (6)}
- C12N 2800/204: of bacterial origin, e.g. BAC
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2840/105: enhancing translation
- C12Y 102/01017: Glyoxylate dehydrogenase (acylating) (1.2.1.17)
- C12Y 102/0701: Oxalate oxidoreductase (1.2.7.10)
- C12Y 208/03002: Oxalate CoA-transferase (2.8.3.2)
- C12Y 208/03016: Formyl-CoA transferase (2.8.3.16)
- C12Y 401/01002: Oxalate decarboxylase (4.1.1.2)
- C12Y 401/01008: Oxalyl-CoA decarboxylase (4.1.1.8)
- C12Y 602/01008: Oxalate--CoA ligase (6.2.1.8)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The disclosure relates generally to bacteria that have been modified to have increased oxalate degrading activity, pharmaceutical compositions including the bacteria, and methods of treating disorders associated with an elevated amount of oxalate, e.g., hyperoxaluria.

## Claims

### Claim 1

A commensal bacterium that has been modified to have increased oxalate degrading activity relative to a similar or otherwise identical bacterium that has not been modified.

### Claim 2 (depends on 1)

The bacterium of claim 1, wherein the bacterium is of a genus selected from the group consisting of Bacteroides, Alistipes, Faecalibacterium, Parabacteroides, Prevotella, Roseburia, Ruminococcus, Clostridium, Oscillibacter, Gemmiger, Barnesiella, Dialister, Parasutterella, Phascolarctobacterium, Propionibacterium, Sutterella, Blautia, Paraprevotella, Coprococcus, Odoribacter, Spiroplasma, Anaerostipes, and Akkermansia.

### Claim 3 (depends on 2)

The bacterium of claim 2, wherein the genus is Bacteroides.

### Claim 4 (depends on 1, 2, 3)

The bacterium of any one of claims 1-3, wherein the similar or otherwise identical bacterium that has not been modified has no detectable oxalate degrading activity.

### Claim 5 (depends on 1, 2, 3, 4)

The bacterium of any one of claims 1-4, wherein the similar or otherwise identical bacterium that has not been modified has no genes known to be involved in oxalate catabolism.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The bacterium of any one of claims 1-5, wherein no naturally occurring member of the same genus as the bacterium has detectable oxalate degrading activity.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The bacterium of any one of claims 1-6, wherein the bacterium comprises one or more transgenes encoding a protein, or a functional fragment or variant thereof, selected from the group consisting of:
(i) an oxalate:formate antiporter (OxlT);
(ii) an oxalate decarboxylase (OXDC)—EC 4.1.1.2;
(iii) an oxalate oxidase (OXO)—EC 1.2.3.4;
(iv) an oxalate oxidoreductase (OOR)—EC 1.2.7.10;
(v) an oxalate-CoA ligase/Oxalyl-CoA synthetase (OXS)—EC 6.2.1.8;
(vi) a formyl-CoA:oxalate CoA-transferase (FCOCT)—EC 2.8.3.16;
(vii) an acetyl-CoA:oxalate CoA-transferase (ACOCT)—EC 2.8.3.19;
(viii) a succinyl-CoA:oxalate CoA-transferase (SCOCT)—EC 2.8.3.2;
(ix) an oxalyl-CoA decarboxylase (OXC)—EC 4.1.1.8;
(x) an oxalyl-CoA reductase/glyoxylate:NADP+oxidoreductase (OXR)—EC 1.2.1.17; and
(xi) a combination of any of the foregoing proteins.

### Claim 8 (depends on 7)

The bacterium of claim 7, wherein the bacterium comprises one or more transgenes encoding an OxIT or a functional fragment or variant thereof, an OXS or a functional fragment or variant thereof, and an OXC or a functional fragment or variant thereof.

### Claim 9 (depends on 8)

The bacterium of claim 8, wherein the bacterium further comprises one or more transgenes encoding a FCOCT or a functional fragment or variant thereof.

### Claim 10 (depends on 8, 9)

The bacterium of claim 8 or 9, wherein the bacterium further comprises one or more transgenes encoding an ACOCT or a functional fragment or variant thereof.

### Claim 11 (depends on 7)

The bacterium of claim 7, wherein the bacterium comprises one or more transgenes encoding an OxIT or a functional fragment or variant thereof, an OXS or a functional fragment or variant thereof, a first OXC or a functional fragment or variant thereof, a second OXC or a functional fragment or variant thereof, a FCOCT or a functional fragment or variant thereof, and an ACOCT or a functional fragment or variant thereof.

### Claim 12 (depends on 7)

The bacterium of claim 7, wherein the bacterium comprises one or more transgenes encoding an OxIT or a functional fragment or variant thereof, a first OXS or a functional fragment or variant thereof, a second OXS or a functional fragment or variant thereof, an OXC or a functional fragment or variant thereof, a FCOCT or a functional fragment or variant thereof, and an ACOCT or a functional fragment or variant thereof.

### Claim 13 (depends on 7)

The bacterium of claim 7, wherein the bacterium comprises one or more transgenes encoding an OxIT or a functional fragment or variant thereof, a first OXS or a functional fragment or variant thereof, a second OXS or a functional fragment or variant thereof, a first OXC or a functional fragment or variant thereof, a second OXC or a functional fragment or variant thereof, a FCOCT or a functional fragment or variant thereof, and an ACOCT or a functional fragment or variant thereof.

### Claim 14 (depends on 7, 8, 9, 10, 11, 12, 13)

The bacterium of any one of claims 7-13, wherein:
(i) the OxIT is an O. formigenes OxIT;
(ii) the OXS is a S. cerevisiae or an A. thaliana OXS;
(iii) the OXC is a S. cerevisiae or an O. formigenes OXC;
(iv) the FCOCT is an E. coli FCOCT; and/or
(v) the ACOCT is an E. coli ACOCT.

### Claim 15 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding a S. cerevisiae OXS, a S. cerevisiae OXC, and an O. formigenes OxIT.

### Claim 16 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an E. coli FCOCT, an O. formigenes OXC, a S. cerevisiae OXS, and an O. formigenes OxIT.

### Claim 17 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an E. coli FCOCT, an O. formigenes OXC, a S. cerevisiae OXS, a S. cerevisiae OXC, an E. coli ACOCT, and an O. formigenes OxIT.

### Claim 18 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an E. coli FCOCT, an O. formigenes OXC, a S. cerevisiae OXS, a S. cerevisiae OXC, an A. thaliana OXS, an E. coli ACOCT, and an O. formigenes OxIT.

### Claim 19 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an E. coli FCOCT, an O. formigenes OXC, an O. formigenes OxIT, an E. coli ACOCT, and a S. cerevisiae OXS.

### Claim 20 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an O. formigenes OxIT, an E. coli FCOCT, a S. cerevisiae OXC, an E. coli ACOCT, a S. cerevisiae OXS, and an A. thaliana OXS.

### Claim 21 (depends on 14)

The bacterium of claim 14, wherein the bacterium comprises one or more transgenes encoding an O. formigenes OxIT, an E. coli FCOCT, a S. cerevisiae OXC, an E. coli ACOCT, and a S. cerevisiae OXS.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The bacterium of any one of claims 1-21, wherein the one or more transgenes are on a plasmid, on a bacterial artificial chromosome, or are genomically integrated.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The bacterium of any one of claims 1-22, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to any one of SEQ ID NOs: 1-31.

### Claim 24 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 16, a nucleotide sequence having at least 80% identity to SEQ ID NO: 26 or SEQ ID NO: 163, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 21.

### Claim 25 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 25, a nucleotide sequence having at least 80% identity to SEQ ID NO: 16, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 21.

### Claim 26 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 25, a nucleotide sequence having at least 80% identity to SEQ ID NO: 16, a nucleotide sequence having at least 80% identity to SEQ ID NO: 26 or SEQ ID NO: 163, a nucleotide sequence having at least 80% identity to SEQ ID NO:
2, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 21.

### Claim 27 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 25, a nucleotide sequence having at least 80% identity to SEQ ID NO: 16, a nucleotide sequence having at least 80% identity to SEQ ID NO: 26 or SEQ ID NO: 163, a nucleotide sequence having at least 80% identity to SEQ ID NO:
14, a nucleotide sequence having at least 80% identity to SEQ ID NO: 2, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 21.

### Claim 28 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 25, a nucleotide sequence having at least 80% identity to SEQ ID NO: 21, a nucleotide sequence having at least 80% identity to SEQ ID NO: 2, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 16.

### Claim 29 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 21, a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 26 or SEQ ID NO: 163, a nucleotide sequence having at least 80% identity to SEQ ID NO: 2, a nucleotide sequence having at least 80% identity to SEQ ID NO: 16, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 14.

### Claim 30 (depends on 23)

The bacterium of claim 23, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 21, a nucleotide sequence having at least 80% identity to SEQ ID NO: 7, a nucleotide sequence having at least 80% identity to SEQ ID NO: 26 or SEQ ID NO: 163, a nucleotide sequence having at least 80% identity to SEQ ID NO: 2, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 16.

### Claim 31 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The bacterium of any one of claims 7-30, wherein at least one of the one or more transgenes is operably linked to a ribosome binding site (RBS).

### Claim 32 (depends on 31)

The bacterium of claim 31, wherein the RBS comprises the nucleotide sequence any one of SEQ ID NOs: 164-230.

### Claim 33 (depends on 32)

The bacterium of claim 32, wherein:
(i) the bacterium comprises a transgene encoding an O. formigenes OxIT operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 212-219;
(ii) the bacterium comprises a transgene encoding a S. cerevisiae OXS operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 172-179;
(iii) the bacterium comprises a transgene encoding an A. thaliana OXS operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 164-171;
(iv) the bacterium comprises a transgene encoding a S. cerevisiae OXC operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 188-195 or 220-230;
(v) the bacterium comprises a transgene encoding an O. formigenes OXC operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 180-187;
(vi) the bacterium comprises a transgene encoding an E. coli FCOCT operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 204-211; and/or
(vii) the bacterium comprises a transgene encoding an E. coli ACOCT operably linked to an RBS comprising the nucleotide sequence of any one of SEQ ID NOs: 196-203.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The bacterium of any one of claims 1-33, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to any one of SEQ ID NOs 96-162:

### Claim 35 (depends on 34)

The bacterium of claim 34, wherein
(i) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 113, a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 128, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 104;
(ii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 155, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 128, a nucleotide sequence having at least 80% identity to SEQ ID NO: 148, a nucleotide sequence having at least 80% identity to SEQ ID NO: 115, a nucleotide sequence having at least 80% identity to SEQ ID NO: 98, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 105;
(iii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 155, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 128, a nucleotide sequence having at least 80% identity to SEQ ID NO: 144, a nucleotide sequence having at least 80% identity to SEQ ID NO: 115, a nucleotide sequence having at least 80% identity to SEQ ID NO: 98, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 105;
(iv) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 147, a nucleotide sequence having at least 80% identity to SEQ ID NO: 104, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO: 97, a nucleotide sequence having at least 80% identity to SEQ ID NO: 131, a nucleotide sequence having at least 80% identity to SEQ ID NO: 136, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 113;
(v) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO:
129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 105, a nucleotide sequence having at least 80% identity to SEQ ID NO: 113, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 96;
(vi) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 105, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 96;
(vii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 139, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 155, a nucleotide sequence having at least 80% identity to SEQ ID NO: 112, a nucleotide sequence having at least 80% identity to SEQ ID NO: 99, a nucleotide sequence having at least 80% identity to SEQ ID NO: 106, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 145;
(viii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 139, a nucleotide sequence having at least 80% identity to SEQ ID NO: 154, a nucleotide sequence having at least 80% identity to SEQ ID NO: 131, a nucleotide sequence having at least 80% identity to SEQ ID NO: 98, a nucleotide sequence having at least 80% identity to SEQ ID NO: 115, a nucleotide sequence having at least 80% identity to SEQ ID NO: 106, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 149;
(ix) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 113, a nucleotide sequence having at least 80% identity to SEQ ID NO: 148, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 105;
(x) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 105;
(xi) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 155, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 128, a nucleotide sequence having at least 80% identity to SEQ ID NO:
144, a nucleotide sequence having at least 80% identity to SEQ ID NO: 115, a nucleotide sequence having at least 80% identity to SEQ ID NO: 98, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 105;
(xii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 105, a nucleotide sequence having at least 80% identity to SEQ ID NO: 113, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 96;
(xiii) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 145, a nucleotide sequence having at least 80% identity to SEQ ID NO: 137, a nucleotide sequence having at least 80% identity to SEQ ID NO: 153, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 105, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 96; or
(xiv) the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 139, a nucleotide sequence having at least 80% identity to SEQ ID NO: 129, a nucleotide sequence having at least 80% identity to SEQ ID NO: 155, a nucleotide sequence having at least 80% identity to SEQ ID NO: 112, a nucleotide sequence having at least 80% identity to SEQ ID NO: 99, a nucleotide sequence having at least 80% identity to SEQ ID NO: 106, and a nucleotide sequence having at least 80% identity to SEQ ID NO: 145.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The bacterium of any one of claims 1-35, wherein the bacterium comprises one or more nucleic acids comprising a nucleotide sequence having at least 80% identity to any one of SEQ ID NOs: 82-95.

### Claim 37 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The bacterium of any one of claims 7-36, wherein at least one of the one or more transgenes is operably linked to at least one constitutive promoter.

### Claim 38 (depends on 37)

The bacterium of claim 37, wherein the promoter is a phage-derived promoter.

### Claim 39 (depends on 37, 38)

The bacterium of claim 37 or 38, wherein the promoter comprises the consensus sequence GTTAA(n)4-7GTTAA(n)34-38TA(n)2TTTG (SEQ ID: 70).

### Claim 40 (depends on 37, 38, 39)

The bacterium of any one of claims 37-39, wherein the promoter comprises SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 71.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The bacterium of any one of claims 1-40, wherein the bacterium has been modified to colonize the human gut with increased abundance, stability, predictability or ease of initial colonization.

### Claim 42 (depends on 41)

The bacterium of claim 41, wherein the bacterium has been modified to increase its ability to utilize a privileged nutrient as carbon source.

### Claim 43 (depends on 42)

The bacterium of claim 42, wherein the bacterium comprises one or more transgenes that increase its ability to utilize a privileged nutrient as carbon source.

### Claim 44 (depends on 42, 43)

The bacterium of claim 42 or 43, wherein the privileged nutrient is a marine polysaccharide.

### Claim 45 (depends on 44)

The bacterium of claim 44, wherein the marine polysaccharide is a porphyran.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The bacterium of any one of claims 41-45, wherein, upon administration to a human subject, the abundance of the bacterium is greater than 1012, 1011, 1010, 109, 108, or 107 cfu per gram of fecal content.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A pharmaceutical composition comprising the bacterium of any one of claims 1-46 and a pharmaceutically acceptable excipient.

### Claim 48 (depends on 47)

The pharmaceutical composition of claim 47, wherein the composition is formulated as a capsule or a tablet.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the capsule is an enteric coated capsule.

### Claim 50 (depends on 47, 48, 49)

The pharmaceutical composition of any one of claims 47-49, wherein the composition further comprises a privileged nutrient.

### Claim 51 (depends on 50)

The pharmaceutical composition of claim 50, wherein the privileged nutrient is a marine polysaccharide.

### Claim 52 (depends on 51)

The pharmaceutical composition of claim 51, wherein the marine polysaccharide is a porphyran.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A method of reducing a level of oxalate in a subject, the method comprising administering the bacterium of any one of claims 1-46 or the pharmaceutical composition of any one of claims 47-52 to the subject.

### Claim 54 (depends on 53)

The method of claim 53, wherein the subject has a disorder associated with an elevated amount of oxalate.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A method of treating a disorder associated with an elevated amount of oxalate in a subject, the method comprising administering the bacterium of any one of claims 1-46 or the pharmaceutical composition of any one of claims 47-52 to the subject.

### Claim 56 (depends on 54, 55)

The method of claim 54 or 55, wherein the disorder is hyperoxaluria.

### Claim 57 (depends on 53, 54, 55, 56)

The method of any one of claims 53-56, further comprising administrating a privileged nutrient to the subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein the privileged nutrient is administered to the subject prior to, at the same time as, or after the bacterium.

### Claim 59 (depends on 58)

The method of claim 58, wherein the privileged nutrient is a marine polysaccharide.

### Claim 60 (depends on 59)

The method of claim 59, wherein the marine polysaccharide is a porphyran.

### Claim 61 (depends on 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 53-60, wherein the bacterium or pharmaceutical composition is administered to the subject every 12 hours, 24 hours, day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, week, 2 weeks, 3 weeks, 4 weeks, month, 2 months, 3 months, 4 months, 5 months, or 6 months.

### Claim 62 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 53-61, wherein the time between consecutive administrations of the bacterium or pharmaceutical composition to the subject is greater than 48 hours.

### Claim 63 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 53-62, wherein the subject is an animal.

### Claim 64 (depends on 63)

The method of claim 63, wherein the subject is a human.
